A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (COSINR Study)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Oct 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Bone metastases; Large cell carcinoma; Liver metastases; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions
Acronyms COSINR Study

12 Sep 2023 Results assessing safety and efficacy of SBRT and ipi/nivo in first line treatment of metastatic NSCLC presented at the 24th World Conference on Lung Cancer
06 Dec 2022 Planned End Date changed from 1 Dec 2024 to 1 Dec 2027.
06 Dec 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com